Patents Examined by Meera Natarajan
-
Patent number: 12037413Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.Type: GrantFiled: August 3, 2021Date of Patent: July 16, 2024Assignee: MINERVA BIOTECHNOLOGIES CORPORATIONInventors: Cynthia Bamdad, Benoit Smagghe
-
Patent number: 12030955Abstract: The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.Type: GrantFiled: November 28, 2018Date of Patent: July 9, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa, Tatsuya Kawa
-
Patent number: 12030929Abstract: Anti-Fn amyloid-like FadA antibodies and compositions are provided and methods of treating cancers, including pancreatic and colorectal, and periodontal diseases. Methods include preventing, reducing development, or treating disease in a subject in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which inhibits or blocks an amyloid-like FadA secreted from Fusobacterium nucleatum (Fn).Type: GrantFiled: August 28, 2023Date of Patent: July 9, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventor: Yiping Han
-
Patent number: 12029761Abstract: The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).Type: GrantFiled: March 26, 2019Date of Patent: July 9, 2024Assignee: SYSTIMMUNE, INC.Inventors: Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Camilla Wang, Zeren Gao, Hui Huang
-
Patent number: 12012461Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.Type: GrantFiled: May 15, 2019Date of Patent: June 18, 2024Assignees: Janssen Biotech, Inc., Stichting VUmcInventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
-
Patent number: 12000833Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.Type: GrantFiled: November 22, 2018Date of Patent: June 4, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Julie Guillermet-Guibert, Thibaut Douche, Emmanuelle Mouton-Barbosa, Odile Schiltz, Marie-Pierre Bousquet, Célia Cintas
-
Patent number: 11987625Abstract: The present disclosure relates to an isolated antibody, or antigen binding fragment thereof, which specifically binds to an extracellular domain of cd300f, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region which comprises: (a) an amino acid sequence that is at least 70% identical to the amino acid sequence represented by seq id no: 1; and/or (b) a complementarity determining region 1 (cdr1) that comprises the amino acid sequence represented by seq id no: 2, a complementarity determining region 2 (cdr2) that comprises an amino acid sequence that is represented by seq id no: 3, and/or a complementarity determining region 3 (cdr3) that comprises an amino acid sequence that is represented by seq id no: 4, compositions comprising the antibody, antigen binding fragment thereof, and uses for therapy.Type: GrantFiled: November 22, 2017Date of Patent: May 21, 2024Assignee: DENDROCYTE BIOTECH PTY LTDInventors: Derek Nigel John Hart, Georgina Jane Clark, Robin Gasiorowski
-
Patent number: 11981729Abstract: We describe a Cnx/ERp57 inhibitor for use in the treatment or prevention of cancer.Type: GrantFiled: August 14, 2023Date of Patent: May 14, 2024Assignee: Agency for Science, Technology and ResearchInventors: Frederic Bard, Anh Tuan Nguyen, Ros Manon
-
Patent number: 11976130Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.Type: GrantFiled: July 17, 2018Date of Patent: May 7, 2024Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der JohannesInventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
-
Patent number: 11969475Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.Type: GrantFiled: October 26, 2023Date of Patent: April 30, 2024Assignee: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
-
Patent number: 11965033Abstract: The present invention relates to a monoclonal mouse antibody produced by the hybridoma cell deposited under ICLC accession number ICLC PD n° 16001. Furthermore, the invention relates to an antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6), respectively. In addition, the invention relates to antibodies recognizing the same epitope.Type: GrantFiled: October 5, 2021Date of Patent: April 23, 2024Assignee: UNIVERSITÀ DEGLI STUDI MAGNA GRAECIA CATANZAROInventor: Pierfrancesco Tassone
-
Patent number: 11958907Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.Type: GrantFiled: September 2, 2020Date of Patent: April 16, 2024Assignee: INNATE PHARMAInventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
-
Patent number: 11952430Abstract: The present invention provides multispecific antigen-binding molecules that bind both a T-cell antigen (e.g., CD3) and a target antigen (e.g., a tumor associated antigen, a viral or bacterial antigen), and which include a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T-cell antigen binding, and uses thereof.Type: GrantFiled: October 17, 2022Date of Patent: April 9, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lauric Haber, Jennifer A. Finney, Ryan McKay, Eric Smith, Chia-Yang Lin
-
Patent number: 11939385Abstract: The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.Type: GrantFiled: May 15, 2018Date of Patent: March 26, 2024Assignee: ALX ONCOLOGY INC.Inventors: Marija Vrljic, Jaume Pons
-
Patent number: 11939379Abstract: Chemically induced dimerizers (AbCIDs) have emerged as one of the most powerful tools to artificially regulate signaling pathways in cells; however, no facile method to identify or design these systems currently exists. The present invention provides a methodology to rapidly generate antibody-based chemically induced dimerizers (AbCIDs) from known small-molecule-protein complexes by selecting for synthetic antibodies that recognize the chemical epitope created by the bound small molecule. Success of this strategy is demonstrated by generating ten chemically-inducible antibodies against the BCL-xL/ABT-737 complex. Three of the antibodies are highly selective for the BCL-xL/ABT-737 complex over BCL-xL alone. Two exemplary important cellular applications of AbCIDs are demonstrated by applying them intracellularly to induce CRISPRa-mediated gene expression and extracellularly to regulate CAR T-cell activation with the small molecule, ABT-737.Type: GrantFiled: May 21, 2018Date of Patent: March 26, 2024Assignee: The Regents of the University of CaliforniaInventors: James A Wells, Zachary B. Hill, Alexander J. Martinko
-
Patent number: 11926666Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: May 3, 2021Date of Patent: March 12, 2024Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Bertram Weiss, Anna-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
-
Patent number: 11918650Abstract: The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 ?g/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.Type: GrantFiled: May 7, 2018Date of Patent: March 5, 2024Assignee: AMGEN INC.Inventors: Jeff Abel, Lingwen Cui, Devrishi Goswami, Joon Huh, Bharadwaj Jagannathan, Sekhar Kanapuram, Arnold McAuley, Michael Schneider, Ananthakrishnan G. Sethuraman, Michael Treuheit, Jun Zhang
-
Patent number: 11905326Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.Type: GrantFiled: June 12, 2020Date of Patent: February 20, 2024Assignee: TeneoBio, Inc.Inventors: Nathan Trinklein, Udaya Rangaswamy, Suhasini Iyer, Kirthana Prabhakar, Harshad Ugamraj
-
Patent number: 11884722Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.Type: GrantFiled: January 20, 2023Date of Patent: January 30, 2024Assignee: JANSSEN BIOTECH, INC.Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
-
Patent number: 11866498Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.Type: GrantFiled: February 8, 2019Date of Patent: January 9, 2024Assignee: Genentech, Inc.Inventors: Diego Ellerman, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess